Maryline Simon

569 total citations
13 papers, 298 citations indexed

About

Maryline Simon is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Maryline Simon has authored 13 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 9 papers in Psychiatry and Mental health and 2 papers in Molecular Biology. Recurrent topics in Maryline Simon's work include Dementia and Cognitive Impairment Research (9 papers), Alzheimer's disease research and treatments (9 papers) and Neuroinflammation and Neurodegeneration Mechanisms (2 papers). Maryline Simon is often cited by papers focused on Dementia and Cognitive Impairment Research (9 papers), Alzheimer's disease research and treatments (9 papers) and Neuroinflammation and Neurodegeneration Mechanisms (2 papers). Maryline Simon collaborates with scholars based in Switzerland, Germany and Sweden. Maryline Simon's co-authors include Kaj Blennow, Niklas Mattsson, John Q. Trojanowski, Oskar Hansson, Valeria Lifke, Udo Eichenlaub, Jon B. Toledo, Simone Wahl, Leslie M. Shaw and Erik Stomrud and has published in prestigious journals such as Scientific Reports, Neurobiology of Aging and Scientific American.

In The Last Decade

Maryline Simon

10 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maryline Simon Switzerland 5 197 175 74 56 46 13 298
Anna L. Svenningsson Sweden 4 275 1.4× 257 1.5× 75 1.0× 47 0.8× 76 1.7× 5 390
Naira Goukasian United States 12 209 1.1× 160 0.9× 49 0.7× 73 1.3× 79 1.7× 23 365
Fadi S. Hanna Al‐Shaikh United States 5 189 1.0× 164 0.9× 52 0.7× 69 1.2× 38 0.8× 5 291
Stijn Servaes Canada 10 124 0.6× 118 0.7× 78 1.1× 53 0.9× 42 0.9× 33 298
Kimberley Mauroo Netherlands 5 248 1.3× 196 1.1× 66 0.9× 34 0.6× 84 1.8× 10 334
Isabel Hernández Spain 12 251 1.3× 177 1.0× 67 0.9× 57 1.0× 130 2.8× 23 461
Nesrine Rahmouni Canada 8 190 1.0× 161 0.9× 41 0.6× 48 0.9× 45 1.0× 39 290
José María Gónzalez‐de‐Echávarri Spain 9 128 0.6× 107 0.6× 57 0.8× 59 1.1× 42 0.9× 19 285
Ina S. Almdahl Norway 10 112 0.6× 154 0.9× 150 2.0× 66 1.2× 35 0.8× 15 362
Guadalupe Fernández‐Villullas Spain 10 135 0.7× 160 0.9× 55 0.7× 60 1.1× 23 0.5× 22 240

Countries citing papers authored by Maryline Simon

Since Specialization
Citations

This map shows the geographic impact of Maryline Simon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maryline Simon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maryline Simon more than expected).

Fields of papers citing papers by Maryline Simon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maryline Simon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maryline Simon. The network helps show where Maryline Simon may publish in the future.

Co-authorship network of co-authors of Maryline Simon

This figure shows the co-authorship network connecting the top 25 collaborators of Maryline Simon. A scholar is included among the top collaborators of Maryline Simon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maryline Simon. Maryline Simon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Maglóczky, Zsófia, et al.. (2024). Ultrastructural analysis of synapses and mitochondria in the hippocampus of depressed patiens. European Psychiatry. 67(S1). S362–S363. 1 indexed citations
2.
Ortner, Marion, Oliver Goldhardt, Janine Diehl‐Schmid, et al.. (2023). Elecsys Cerebrospinal Fluid Immunoassays Accurately Detect Alzheimer’s Disease Regardless of Concomitant Small Vessel Disease. Journal of Alzheimer s Disease. 93(4). 1537–1549. 2 indexed citations
3.
Simon, Maryline. (2023). Deep Sleep Gives Your Brain a Deep Clean. Scientific American. 32(2). 12–12.
4.
Ortner, Marion, Oliver Goldhardt, Janine Diehl‐Schmid, et al.. (2022). Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration. The Journal of Prevention of Alzheimer s Disease. 9(3). 491–498. 6 indexed citations
5.
Milà‐Alomà, Marta, Gemma Salvadó, Mahnaz Shekari, et al.. (2021). Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer. The Journal of Prevention of Alzheimer s Disease. 8(1). 68–77. 11 indexed citations
6.
Sánchez‐Benavides, Gonzalo, Marc Suárez‐Calvet, Marta Milà‐Alomà, et al.. (2021). Amyloid-β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. Neurobiology of Aging. 104. 24–31. 12 indexed citations
7.
Molinuevo, José Luís, Marta Milà‐Alomà, Gemma Salvadó, et al.. (2020). Emerging beta‐amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. Alzheimer s & Dementia. 16(S4). 1 indexed citations
8.
Suárez‐Calvet, Marc, Marta Milà‐Alomà, Gemma Salvadó, et al.. (2020). Amyloid‐β, tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer’s continuum. Alzheimer s & Dementia. 16(S4).
9.
Milà‐Alomà, Marta, Gemma Salvadó, Juan Domingo Gispert, et al.. (2020). Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer s & Dementia. 16(10). 1358–1371. 136 indexed citations
10.
Blennow, Kaj, Leslie M. Shaw, Erik Stomrud, et al.. (2019). Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays. Scientific Reports. 9(1). 19024–19024. 127 indexed citations
11.
Blennow, Kaj, Jeffrey L. Dage, Sterling C. Johnson, et al.. (2019). P2‐231: EXPLORING THE NEED FOR ROBUST BIOMARKER ASSAYS IN ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES. Alzheimer s & Dementia. 15(7S_Part_13).
12.
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna L. Svenningsson Breakdown of academic impact, for papers by Naira Goukasian Breakdown of academic impact, for papers by Fadi S. Hanna Al‐Shaikh Breakdown of academic impact, for papers by Stijn Servaes Breakdown of academic impact, for papers by Kimberley Mauroo Breakdown of academic impact, for papers by Isabel Hernández Breakdown of academic impact, for papers by Nesrine Rahmouni Breakdown of academic impact, for papers by José María Gónzalez‐de‐Echávarri Breakdown of academic impact, for papers by Ina S. Almdahl Breakdown of academic impact, for papers by Guadalupe Fernández‐Villullas
Rankless by CCL
2026